875781-15-0

Basic information

• Product Name: 5-Bromo-2-fluoropyridine-3-carboxaldehyde
• Synonyms: 5-Bromo-2-fluoro-pyridin-3-carbaldehyde;5-Bromo-2-fluoropyridine-3-carboxaldehyde;5-Bromo-2-fluoro-3-pyridinecarboxaldehyde;5-Bromo-2-fluoro-3-formylpyridine;5-bromo-2-fluoronicotinaldehyde;5-Bromo-2-fluoropyridine-3-carboxaldehyde, 5-Bromo-2-fluoro-3-formylpyridine;3-Pyridinecarboxaldehyde, 5-broMo-2-fluoro-
• CAS NO: 875781-15-0
• Molecular Formula: C₆H₃BrFNO
• Molecular Weight: 204
• Product Categories: Fluorine series;Building Blocks;Pyridine
• Mol File: 875781-15-0.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 258.168 °C at 760 mmHg
• Flash Point: 109.936 °C
• Appearance: Off-white to pale yellow/Powder
• Density: 1.778 g/cm³
• Vapor Pressure: 0.014mmHg at 25°C
• Refractive Index: 1.591
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -4.59±0.20(Predicted)
• CAS DataBase Reference: 5-Bromo-2-fluoropyridine-3-carboxaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-2-fluoropyridine-3-carboxaldehyde(875781-15-0)
• EPA Substance Registry System: 5-Bromo-2-fluoropyridine-3-carboxaldehyde(875781-15-0)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 875781-15-0(Hazardous Substances Data)

Usage

Uses

5-Bromo-2-fluoro-3-pyridinecarboxaldehyde is used in the synthesis of [2,3-d]pyrimidine derivatives useful as Raf kinase inhibitors. Also used in the preparation of XIa inhibitors.

InChI:InChI=1/C6H3BrFNO/c7-5-1-4(3-10)6(8)9-2-5/h1-3H

Upstream product

• 766-11-0 5-bromo-2-fluoropyridine 
• 109-94-4 formic acid ethyl ester 
• 2591-86-8 N-Formylpiperidine 

Downstream Products

• 1111637-73-0 1-(5-bromo-2-fluoropyridin-3-yl)ethanol 
• 875781-17-2 5-bromo-7-azaindazole 
• 1196156-42-9 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid methyl ester 
• 952182-02-4 1H-pyrazolo[3,4-b] pyridine-5-carboxylic acid 
• 1234616-67-1 1H-pyrazolo[3,4-b]pyridine-5-carbonitrile 

Relevant articles and documents

PROCESS FOR PREPARING ALKYNYL-CONTAINING COMPOUND AND INTERMEDIATE THEREOF

Disclosed are processes for preparing alkylnyl-containing compounds of Formula (I) as shown below, intermediates and related compounds thereof. Pharmaceutical compositions comprising the compounds and methods of treating cancer thereof are also disclosed.

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

7-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 7-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

7-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 7-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.